Journal
JOURNAL OF IMMUNOTHERAPY
Volume 27, Issue 6, Pages 478-479Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00002371-200411000-00008
Keywords
melanoma; immunotherapy; uveitis; autoimmunity; CTLA-4 antibody
Categories
Funding
- Intramural NIH HHS [Z01 SC003811-32] Funding Source: Medline
Ask authors/readers for more resources
Cytotoxic T Lymphocyte-associated antigen 4 (CTLA-4) is an important costimultory receptor expressed on activated T cells. CTLA-4 blockade using a monoclonal antibody (mAb) in conjunction with tumor vaccines has improved tumor responses in animal models and enhanced numerous models of T cell-associated autoimmune diseases. Two patients with stage IV metastatic melanoma vaccinated with the gp 100 melanocyte/melanoma differentiation antigen either before or during anti-CTLA-4 mAb therapy developed uveitis, This is the first report of autoimmune disease involving the eye in patients treated with anti-CTLA-4 mAb. This suggests that CTLA-4 is an important regulatory molecule for maintenance of tolerance to melanosomal antigens and prevention of uveitis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available